RxDoctor Payments Data

Stephen Mason, MD

MOHS-Micrographic Surgery · Hot Springs, ARNPI 1134141484

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,462 of the $1,732 with a category attached, or 84.4%. 13 manufacturers reported payments, led by Johnson & Johnson at 25.2% of the total. Reporting peaked in 2023 at $529 and has fallen 57.9% since, to $223 in 2025.

$1,732in general payments, 2019–2025

Across 81 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$436
  • Novartis$375
  • Amgen$371
  • AbbVie$158
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$145
  • Sun Pharmaceutical Industries Inc.$67
  • plus $180 from 7 others

What the payments were for

  • Food & beverage$1,46284%
  • Education$27016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$593,960
Medicare patients
1,043
Services billed
4,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$253,341
OtezlaApremilast13$65,760
Fluorouracil127$8,842
Mometasone Furoate204$4,158
Betamethasone Dipropionate69$2,953
Clobetasol Propionate49$2,891
Tacrolimus18$2,254
Doxycycline Hyclate115$1,600
CiclopiroxCiclopirox Olamine37$1,447
Metronidazole30$1,254
Imiquimod38$1,098
Triamcinolone Acetonide55$849
Ciclopirox12$702
Mupirocin75$547
Clindamycin Phosphate18$449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$371$65,76013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few mohs-micrographic surgery providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other mohs-micrographic surgery in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →